| request information: |
|
| name: | Amyloid Precursor Protein alpha (444-612), Secreted human |
| cat_no: | S8190 |
| gene id: | human APP(351) |
| brand: | SIGMA |
| prod_type: | Chemical |
| name_suffix: | >90% (SDS-PAGE), recombinant, expressed in Escherichia coli (N-terminal histidine tagged), buffered aqueous solution |
| storage temp.: | -70C |
| storage: | -70C |
| form: | buffered aqueous solution |
| physical form: | Solution in phosphate buffered saline, pH 7.4, 0.2 mum filtered. |
| shipped in: | dry ice |
| syns: | sAPPalpha (444-612) |
| unspsc_code: | 12352209 |
| wgk: | 3 |
| mdl_no: | MFCD03791390 |
| application: | This fragment enables study of biological effects without the interference of the sAPPalpha N-terminal cysteine rich domain and the RERMS peptide domain activities (e.g. activation of pro-inflammatory effects of microglial cells, binding to heparan sulfate proteoglycan, binding ApoE proteins and inducing fibroblast proliferation, and neurite outgrowth in neuroblastoma cells). |
| mol wt: | apparent mol wt 33 kDa by SDS-PAGE |
| biochem/physiol actions: | Secreted amyloid precursor protein alpha (sAPPalpha) is a 612 amino acid protein produced from the ubiquitously expressed beta-Amyloid precursor protein (betaAPP), 695 isoform, by alpha-secretase cleavage. The sAPPalpha (444-612) fragment was designed to contain a sequence that is linked to the attenuation of glutamate exocitotoxicity and to the promotion of neurite outgrowth. In addition, it contains the C-terminal domain corresponding to sAPPalpha (597-612) that acts as a heparin-binding domain. |
| purity: | >90% (SDS-PAGE) |
| assay: | >90% (SDS-PAGE) |
order or
more information: | company product webpage |